Clinical Trial Update: Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating daptomycin as an adjuvant therapy for enterococcal native valve endocarditis was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterococcal Endocarditis

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Endocarditis, Bacterial | Phase 4 | Status: TERMINATED | Results posted: 2017-05-03